TheraRadar
← Back
Data updated: Mar 29, 2026

YICHANG HUMANWELL

CardiovascularInfectious DiseaseNeurology
Generics

YICHANG HUMANWELL is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Neurology.

2018
Since
19
Drugs
-
Trials
334
Approved (2yr)

Key Drugs

FENOFIBRIC ACID
choline fenofibrate
Metabolic
PPAR alpha 2 indications · 2013

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

BUPROPION HYDROCHLORIDE 2026-02-25
Labeling
MICAFUNGIN SODIUM 2026-02-24
VENLAFAXINE HYDROCHLORIDE 2026-01-30
Labeling
DIVALPROEX SODIUM 2026-01-29
Labeling
DIVALPROEX SODIUM 2026-01-29
Labeling
DIVALPROEX SODIUM 2026-01-28
Labeling
DIVALPROEX SODIUM 2026-01-28
Labeling
DIVALPROEX SODIUM 2026-01-24
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 40%
2 drugs
Infectious Disease 20%
1 drugs
Neurology 20%
1 drugs
Immunology 20%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Merck big-pharma
Infectious Disease, Cardiovascular, Immunology
AbbVie big-pharma
Immunology, Neurology, Infectious Disease
PAI HOLDINGS PHARM big-pharma
Infectious Disease, Neurology, Cardiovascular, Immunology
Johnson & Johnson big-pharma
Immunology, Infectious Disease, Cardiovascular
GSK big-pharma
Infectious Disease, Immunology, Neurology